Subchronic haloperidol treatment decreases the in vivo release of tachykinins in rat substantia nigra.
Microdialysis combined with sensitive radioimmunoassays was used to measure the in vivo release of substance P (SP) and neurokinin A (NKA) in the rat substantia nigra. The effect of acute and subchronic haloperidol treatment (0.5 mg/kg) on the basal and potassium-evoked release was studied. No significant effect was observed after a single injection. However, pretreatment with haloperidol for 10 days decreased the potassium-induced release of SP and NKA by 25 and 27%, respectively. The basal overflow of NKA was reduced by 29%, while no significant effect could be seen on the basal release of SP.
Lindefors
N
N
Department of Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Brodin
E
E
Ungerstedt
U
U
D000818:Animals; D006220:Haloperidol / Q000494:pharmacology*; D008297:Male; D015288:Neurokinin A / Q000378:metabolism; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D013373:Substance P / Q000378:metabolism; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism*; D015320:Tachykinins / Q000378:metabolism*; D013997:Time Factors
D015320:Tachykinins; D013373:Substance P; D015288:Neurokinin A; D006220:Haloperidol